A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo
Authors:
- Rajesh PuranikRPRajesh Puranik
- Shisan BaoSBShisan Bao
- Antonio M. BoninABAntonio M. Bonin
- Ravinder KaurRKRavinder Kaur
- Jane E. WederJWJane E. Weder
- Llewellyn CasboltLCLlewellyn Casbolt
- Trevor W. HambleyTHTrevor W. Hambley
- Peter A. LayPLPeter A. Lay
- Philip J. BarterPBPhilip J. Barter
- Kerry-Anne RyeKRKerry-Anne Rye
Open Access
- 6 February 2016
- journal article
- research article
- Published by Springer Nature in Cell & Bioscience
- Vol. 6 (1) , 1-7
Abstract
The ability of Zn(II) and Cu(II) metal complexes of non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit acute arterial inflammation in vivo has been studied. When acute vascular inflammation was induced in normocholesterolemic New Zealand White rabbits by inserting a non-occlusive silastic collar around the common carotid artery, a single oral dose of Cu(II)-indomethacin (Cu(II)Indo, 3 mg/kg) administered by laparotomy achieved a 67 % (8.2 ± 1.7 vs. 2.7 ± 0.4 image units, p < 0.05) reduction in endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) but did not inhibit endothelial intercellular adhesion molecule (ICAM-1) expression significantly. Treatment with Cu(II)-acemetacin (Cu(II)ACM, 3 mg/kg) led to a profound 88 % (8.2 ± 1.7 vs. 1.0 ± 0.5 image units, p < 0.01) reduction in endothelial VCAM-1 expression but did not inhibit ICAM-1 expression, while treatment with Zn(II)-acemetacin (Zn(II)ACM, 3 mg/kg) led to an 84 % (19.3 ± 1.0 vs. 3.1 ± 1.2 image units, p < 0.01) reduction in endothelial ICAM-1 expression and did not inhibit VCAM-1 expression. No adverse gastric, hepatic or renal effects were observed in treated animals. These findings provide the “proof of concept” that this novel class of drug, where there is complexation of NSAIDs with metal ions, has substantial anti-inflammatory effects in an animal model of acute vascular inflammation with the possibility of low rates of adverse effects.Keywords
Funding Information
- The Australian Research Council
- Medical Therapies Ltd
- the Neil Hamilton Fairley
This publication has 20 references indexed in Scilit:
- Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safetyBritish Journal of Pharmacology, 2008
- ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID UseJACC, 2008
- Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular riskBMC Musculoskeletal Disorders, 2007
- Use of Nonsteroidal Antiinflammatory DrugsCirculation, 2007
- Synthesis, crystal structures, and anti-convulsant activities of ternary [ZnII(3,5-diisopropylsalicylate)2], [ZnII(salicylate)2] and [ZnII(aspirinate)2] complexesJournal of Inorganic Biochemistry, 2004
- Gastrointestinal Toxicity, Antiinflammatory Activity, and Superoxide Dismutase Activity of Copper and Zinc Complexes of the Antiinflammatory Drug IndomethacinChemical Research in Toxicology, 2002
- Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart diseaseJACC, 2002
- High Superoxide Dismutase Activity of a Novel, Intramolecularly Imidazolato-Bridged Asymmetric Dicopper(II) Species. Design, Synthesis, Structure, and Magnetism of Copper(II) Complexes with a Mixed Pyrazole−Imidazole Donor SetInorganic Chemistry, 1997
- Immunoturbidimetry of serum apolipoproteins A-I and B on the Cobas Bio centrifugal analyzer: Method validation and reference valuesClinical Biochemistry, 1994
- Über die Behandlung rheumatischer Erkrankungen mit einer Kupfer-Natrium-Salizylat-Komplexverbindung (Permalon)DMW - Deutsche Medizinische Wochenschrift, 1952